Although the evidence for SGLT2 inhibitors' cardioprotective effects in ATTR cardiac amyloidosis is still being studied [2], we should be aware of perioperative metabolic and electrolyte disorders that may arise secondary to our patients’ treatment. This evidence concerns the gene SLC5A2 and Abnormal blood ion concentration.